Pfizer Chief Executive Officer Albert Bourla , 60, back in August had contacted COVID and had started a course of the company's oral COVID-...

Pfizer Inc Chief Executive Officer Albert Bourla said he had started a course of the company's oral COVID-19 antiviral treatment, Paxlovid,...

"It's easy to do something only against Omicron. What is scientifically and technically more challenging ... is to be effective against eve...

Pfizer has signed a voluntary licensing with UN-backed Medicines Patent Pool (MPP) allowing the latter to grant sub-licences of Paxlovid to...

The $1 million award is granted each year to a person for their professional achievements, contributions to humanity and commitment to Jewi...

A vaccine focused directly on the Omicron variant would also guard against breakthrough infections of a strain that has proven highly conta...

Pfizer's chief executive Dr Albert Bourla told the BBC that he is of the view that annual vaccinations would be needed to maintain a "very ...

American pharmaceutical company Pfizer and German company BioNTech pledged on Friday to deliver 2 billion doses of their Covid-19 vaccine t...

The Indian government had last month allowed emergency use approval for imported vaccines which have been granted similar approvals by the ...

These medicines, valued at more than USD 70 million, will be made available immediately, said company's Chairman.

Pfizer hopes that vaccinations of the group could begin before the next school year, Albert Bourla, Pfizer's chairman and chief executive, ...

Wall Street analysts on average expect Pfizer to earn $3.07 per share, according to IBES data from Refinitiv.

Bourla, speaking on a call with reporters on Tuesday, also reiterated confidence in Pfizer's ability to deliver its mRNA vaccine, developed...

"Today's Emergency Use Authorisation in the UK marks a historic moment in the fight against Covid-19," said Pfizer CEO Albert Bourla.

In an SEC filing on late Tuesday, Bourla disclosed that he has sold 62 per cent of his stock holdings, or 1,32,508 shares, at $41.94 per sh...

Read, who was appointed CEO in December 2010, will become the executive chairman of Pfizer's board from Jan. 1.